UNLABELLED: The completion of the human genome project and the accelerated discovery of genes responsible for single gene disorders will allow for the preventive screening of carriers and patients. Accuracy and reliability of analytic tests are major demands on technologies used in a diagnostic screening environment. The consistency of results and the potential of multiplexing suggest mass spectrometry as the method of choice for large-scale genetic screening programs. The added ability to analyze other large molecules such as peptides and proteins further underlines the versatility and usefulness of this technology. We describe the use of mass spectrometry for screening of sickle cell disease at the level of DNA and protein. CONCLUSION: Analytic methods are needed for large-scale screening and diagnostic applications that are highly accurate, fully automated and cost-effective. The precise measurement of molecular weights and the use of high fidelity enzymes to produce diagnostic products make mass spectrometry the method of choice for DNA and protein screening procedures.
UNLABELLED: The completion of the human genome project and the accelerated discovery of genes responsible for single gene disorders will allow for the preventive screening of carriers and patients. Accuracy and reliability of analytic tests are major demands on technologies used in a diagnostic screening environment. The consistency of results and the potential of multiplexing suggest mass spectrometry as the method of choice for large-scale genetic screening programs. The added ability to analyze other large molecules such as peptides and proteins further underlines the versatility and usefulness of this technology. We describe the use of mass spectrometry for screening of sickle cell disease at the level of DNA and protein. CONCLUSION: Analytic methods are needed for large-scale screening and diagnostic applications that are highly accurate, fully automated and cost-effective. The precise measurement of molecular weights and the use of high fidelity enzymes to produce diagnostic products make mass spectrometry the method of choice for DNA and protein screening procedures.
Authors: K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun Journal: Proc Natl Acad Sci U S A Date: 2001-01-02 Impact factor: 11.205
Authors: Matthew J McGinniss; Rebecca Chen; Victoria M Pratt; Arlene Buller; Franklin Quan; Charles M Strom; Weimin Sun; Beryl Crossley Journal: J Mol Diagn Date: 2007-02 Impact factor: 5.568
Authors: Fang Yang; Xiang Ding Chen; Li Jun Tan; Jie Shen; Ding You Li; Fang Zhang; Bao Yong Sha; Hong Wen Deng Journal: Biomed Environ Sci Date: 2014-05 Impact factor: 3.118
Authors: Dong-Hai Xiong; Xiao-Gang Liu; Yan-Fang Guo; Li-Jun Tan; Liang Wang; Bao-Yong Sha; Zi-Hui Tang; Feng Pan; Tie-Lin Yang; Xiang-Ding Chen; Shu-Feng Lei; Laura M Yerges; Xue-Zen Zhu; Victor W Wheeler; Alan L Patrick; ClareAnn H Bunker; Yan Guo; Han Yan; Yu-Fang Pei; Yin-Pin Zhang; Shawn Levy; Christopher J Papasian; Peng Xiao; Y Wang Lundberg; Robert R Recker; Yao-Zhong Liu; Yong-Jun Liu; Joseph M Zmuda; Hong-Wen Deng Journal: Am J Hum Genet Date: 2009-02-26 Impact factor: 11.025